Pharmaceutical Industry Cites Challenges in Collecting Quality Metrics Data from CMOs
This article was originally published in The Gold Sheet
Executive Summary
The pharmaceutical industry is grappling with some logistical challenges in devising ways to collect quality metrics from CMOs under FDA’s proposed quality metrics program. Some industry members question the feasibility of collecting this information while others say that it is possible, but involves much upfront work and planning.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.